Compare Synopsys, Inc. (SNPS) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs TransMedics Group Inc — how do they compare? Synopsys, Inc. trades at $414.35 (market cap $78.68B), while TransMedics Group Inc trades at $87.56 (market cap $3.10B). The key difference: Synopsys, Inc. is far larger — about 25.4× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Synopsys, Inc. nearer its low. Which is the better fit depends on your goals.
| SNPS | TMDX | |
|---|---|---|
Market Cap | $78.68B | $3.10B |
Sector | Technology | Technology |
52-Week High | $625.80 | $150.42 |
52-Week Low | $372.33 | $61.99 |
Enterprise Value | $87.04B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $411.68, down 1.04% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish overall signal despite recent volatility, with strong analyst support (82.76% buy ratings) and a consensus price target of $551.00. Recent earnings beats and strategic moves like the Ansys acquisition highlight robust growth prospects in the semiconductor design software space, though high valuation multiples and significant cash flow volatility warrant caution.
The outlook for SNPS remains positive driven by AI-driven demand and recurring revenue streams, but investors face risks from elevated valuations, integration challenges from acquisitions, and semiconductor cycle sensitivity. The stock's current price near key support levels offers a potential entry point for long-term growth investors, contingent on sustained execution and market conditions.
TransMedics Group (TMDX) trades at $86.43, down 2.24% amid recent earnings misses but maintains strong analyst support with a $99.57 consensus target. The stock shows bullish technical signals with support at $84-87, though RSI levels suggest overbought conditions. Fundamentally, the company demonstrates robust profitability with 58.69% gross margins and 22.69% net income margins, despite recent quarterly earnings falling short of expectations.
Investment outlook remains positive given strong institutional backing and growth potential in organ transplant technology, though risks include ongoing fiduciary investigations and margin pressure from increased operating costs. The stock offers 15% upside to consensus targets but requires monitoring of Q3 earnings performance and legal developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
